Clinical study on the influence of a fixed-dose combination of famotidine with calcium carbonate and magnesium hydroxide on the bioavailability of famotidine

Arzneimittel-Forschung/Drug Research

Volumn 58, Issue 11, 2008, Pages 581-584

  Zhai, Qing ^a   Fu, Jun ^a,b   Huang, Xia ^a   Xu, Bin ^a   Yuan, Yao Zong ^a   Jiang, Tao ^a   Rong, Zheng Xing ^a   Chen, Hong Zhuan ^a  

^a SHANGHAI JIAO TONG UNIVERSITY SCHOOL OF MEDICINE   (China)

^b 1st People's Hosp of Shanghai City   (China)

Author keywords

Antacids; Calcium carbonate, fixed dose combination, interaction with famotidine; CAS 76824 35 6; Famotidine, bioavailability, fixed dose combination, pharmacokinetics; Histamine H2 receptor antagonists

Indexed keywords

CALCIUM CARBONATE; CALCIUM CARBONATE PLUS FAMOTIDINE PLUS MAGNESIUM HYDROXIDE; FAMOTIDINE; MAGNESIUM HYDROXIDE; UNCLASSIFIED DRUG;

ADULT; AREA UNDER THE CURVE; ARTICLE; CHEWABLE TABLET; CHINESE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG FORMULATION; DRUG HALF LIFE; FEMALE; HUMAN; HUMAN EXPERIMENT; MALE; MAXIMUM PLASMA CONCENTRATION; NORMAL HUMAN; RANDOMIZED CONTROLLED TRIAL;

EID: 57649116993     PISSN: 00044172     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-0031-1296560     Document Type: Article

References (13)

1. Robinson M, Rodriguez-Stanley S, Ciociola AA, Filinto J, Zubaidi S, Miner PB, et al., Synergy between low-dose ranitidine and antacid in decreasing gastric and oesophageal acidity and relieving meal-induced heartburn. Alimentary Pharmacol Ther. 2001;15:1365-1374
2. Adachi K, Komazawa Y, Mihara T, Azumi T, Fujisawa T, Katsube T, et al., Comparative study of the speed of acid-suppressing effects of oral administration of cimetidine and famotidine. J Gastroenterol Hepatol. 2005;20:1012-1015.
3. 2-receptor antagonists (ranitidine, famotidine) on intragastric acidity. Alimentary Pharmacol Ther. 1998;12:337-342.
4. Holtmeier W, Holtmann G, Caspary WF, Weingärtner U, On-demand treatment of acute heartburn with the antacid hydrotalcite compared with famotidine and placebo: randomized double-blind cross-over study. J Clin Gastroenterol. 2007;41:564-70
5. 2-receptor antagonists. Alimentary Pharmacol Ther. 1994;8:123-126.
6. Dowling TC, Frye RF, Determination of famotidine in human plasma and urine by high-performance liquid chromatography. J Chromatogr B Biomed Sci Appl. 1999;732:239-243.
7. Chinese pharmacopoeia. Beijing: Chemistry Industry Press; 2005. p. 173-176.
8. Guidance for industry statistical approaches to establishing bioequivalence. FDA (2001) Available at: http://www.fda.gov/cder/guidance/index. htm.
9. Hauck WW, Parekh A, Lesko LJ, Limits of 80 %-125 % for AUC and 70 %-143 % for Cmax. What is the impact on bioequivalence studies? Int J Clin Pharmacol Ther. 2001;39:350-355.
10. Maton PN, Burton ME, Antacids revisited: a review of their clinical pharmacology and recommended therapeutic use. Drugs. 1999;57:855-870.
11. Sasowski DC, Drug interactions with antacids. Mechanisms and clinical significance Drug Saf.1994;11:395-407.
12. Lin JH, Chremos AN, Kanovsky SM, Schwartz S, Yeh KC, Kann J, Effects of antacids and food on absorption of famotidine. Br J Clin Pharmacol. 1987;24:551-553.
13. Echizen H, Ishizaki T, Clinical pharmacokinetics of famotidine. Clin Pharmacokinet. 1991;21:178-194.